Altered gut microbiota composition and metabolism in Parkinson’s disease
Objective: To define changes in gut microbiota composition and metabolism to enable identification of novel therapeutic targets and strategies for disease modification. Background: Multiple cohort…Muscle Augmentation Paradox: Contrasting Therapeutic Approaches in Myasthenia Gravis and Parkinson’s Disease
Objective: This exploration aims to dissect the therapeutic paradox presented by muscle augmentation strategies in Myasthenia Gravis (MG) and Parkinson's Disease (PD), offering a comparative…Differentiating the Local Field Potential Oscillations in Low and Beta Range in Parkinson`s and Dystonic Movement Disorder
Objective: To framework the novel data of subcortical oscillations in Parkinson`s and dystonic patients for the comparison of local field oscillatory (low, beta) influence amongst…Free-Viewing Eye Tracking and the Effect of Levodopa in Parkinson’s Disease
Objective: The objective of our study is to determine whether differences in oculomotor function and blink rate correlate to the off-and on- medication state in a cohort of…Improving awareness of motor fluctuations in Parkinson’s Disease: an educational patient support program using a waist-worn device.
Objective: To describe the utility of an educational patient support program designed to improve awareness of motor fluctuations (MF) and provide education on motor and…Addressing Patient Needs: Enhancing Patient-Centered Care at the Movement Disorders Center
Objective: To define patients’ needs and enhance educational and quality improvement initiatives at our center. Background: Patient-centered care is critical for the managing the symptoms…Predictors of Response to Botulinum Toxin Treatment in Patients With Hemifacial Spasm:A Prospective Study
Objective: To study the predictors of Good and Bad outcome and the impact on quality of life of patients with HFS following Botulinum toxin treatment.…Lower plasma piperine levels in Parkinson’s disease: a PPMI metabolomics analysis
Objective: To explore piperine as a potential biomarker for Parkinson’s disease (PD) among GBA and LRRK2 mutation carriers and non-carriers. Background: Piperine is a yellow…TOPAS-MSA: Targeting Oligomer Pathology of Alpha-Synuclein – A Study Evaluating the Safety and Efficacy of Emrusolmin in Patients with Multiple System Atrophy
Objective: The objective of the TOPAS-MSA study is to assess the safety and efficacy of emrusolmin (anle138b/TEV-56286), an orally bioavailable small molecule targeting aggregated α-synuclein,…Prevalence of autonomic symptoms in Multiple System Atrophy on the background of probable RBD
Objective: To discover whether having probable rapid eye movement sleep behavior disorder (RBD) affects prevalence of particular autonomic symptoms, namely falls, constipation and urinary incontinence…
- « Previous Page
- 1
- …
- 111
- 112
- 113
- 114
- 115
- …
- 181
- Next Page »